GrifolsGRFS +0.48%84 PB Ratio is 0.80 as of Jun. 28, 2026, which is 73% below its 10-year median of 2.94. GuruFocus rates GRFS with a GF Score™ of 84/100 and a GF Value™ of $8.87 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 923 Drug Manufacturers companies, Grifols ranks better than 70.1% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-28), Grifols's share price is $7.39. Grifols's Book Value per Share for the quarter that ended in Mar. 2026 was $9.27. Hence, Grifols's PB Ratio of today is 0.80.
Good Sign:
Grifols SA stock PB Ratio (=1.14) is close to 1-year low of 1.11.
The historical rank and industry rank for Grifols's PB Ratio or its related term are showing as below:
GRFS'
s PB Ratio Range Over the Past 10 Years
Min: 0.95 Med: 2.94 Max: 5.1
Current: 1.14
During the past 13 years, Grifols's highest PB Ratio was 5.10. The lowest was 0.95. And the median was 2.94.
GRFS's PB Ratio is ranked better than 70.1% of 923
companies
in the Drug Manufacturers industry
Industry Median: 1.81
vs GRFS: 1.14
During the past 3 years, the average Book Value Per Share Growth Rate was -2.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 0.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 5.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Grifols was 104.80% per year. The lowest was -2.40% per year. And the median was 11.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Grifols PB Ratio Related Terms
Grifols PB Ratio Historical Data
* Premium members only.
The historical data trend for Grifols's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Grifols's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's PB Ratio distribution charts can be found below:
* The bar in red indicates where Grifols's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Grifols's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Grifols (GRFS) has a PB Ratio of 0.80 as of Jun. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Grifols and its competitors. This is 73% below median its historical median of 2.94. Over the past decade, Grifols' PB Ratio has ranged from 0.95 to 5.10. According to the industry distribution chart, Grifols ranks #276 out of 923 companies in the Drug Manufacturers industry, placing it in the top 29.9%.
Is Grifols' PB Ratio too high?
Grifols' current PB Ratio of 0.80 is 73% below median its 10-year median of 2.94. Over the past 10 years, this metric has ranged from a low of 0.95 to a high of 5.10. The Drug Manufacturers industry median PB Ratio is 1.81. Grifols' value of 0.80 is 55.8% below this industry median. Based on the distribution chart, Grifols ranks #276 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grifols has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #276 out of 923 companies for PB Ratio. This puts Grifols in the upper half of its industry. The industry median PB Ratio is 1.81. Grifols' value of 0.80 is 55.8% below this benchmark. Historically, Grifols' own PB Ratio has ranged from 0.95 to 5.10 over the past decade. While the company's 10-year median is 2.94 vs. the industry median of 1.81, Grifols has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.81, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current PB Ratio of 0.80 is 55.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current PB Ratio is 0.80, which is 73% below median its own 10-year median of 2.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.87, compared to a current price of $7.39 — trading 16.7% below its estimated fair value. The current PB Ratio is 0.80, which is 73% below median its 10-year median of 2.94 and 55.8% below the Drug Manufacturers industry median of 1.81. Grifols' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Grifols (GRFS), the current PB Ratio is 0.80 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (GRFS) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of $7.39 is trading 16.7% below its estimated GF Value™ of $8.87.
GuruFocus considers Grifols to be Modestly Undervalued.
Key valuation signals for GRFS:
PB Ratio: 0.80 (73% below median its 10-year median of 2.94)
GF Value™: $8.87 vs. price of $7.39 (16.7% below fair value)
Industry Position: 55.8% below the Drug Manufacturers median (#276 of 923)
No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score
Get the complete analysis for GRFS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRFS has been successfully added to your 
